Kimio Yonesaka

Publication Activity (10 Years)

Years Active: 2017-2021
Publications (10 Years): 8

Top Topics

Tyrosine Kinase

Positive Breast Cancer

Small Cell Lung Cancer

Top Venues

Scientific reports

Clinical cancer research : an official journal of the American Association for Cancer Research

British journal of cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Shinichiro Suzuki, Kimio Yonesaka, Takeshi Teramura, Toshiyuki Takehara, Ryoji Kato, Hitomi Sakai, Koji Haratani, Junko Tanizaki, Hiasto Kawakami, Hidetoshi Hayashi, Kazuko Sakai, Kazuto Nishio, Kazuhiko Nakagawa
KRAS Inhibitor Resistance in MET-Amplified KRAS G12C Non-Small Cell Lung Cancer Induced By RAS- and Non-RAS-Mediated Cell Signaling Mechanisms. Clinical cancer research : an official journal of the American Association for Cancer Research 27 (20) (2021)
Kimio Yonesaka, Junko Tanizaki, Osamu Maenishi, Koji Haratani, Hiasto Kawakami, Kaoru Tanaka, Hidetoshi Hayashi, Kazuko Sakai, Yasutaka Chiba, Asuka Tsuya, Hiroki Goto, Eri Otsuka, Hiroaki Okida, Maki Kobayashi, Ryoto Yoshimoto, Masanori Funabashi, Yuuri Hashimoto, Kenji Hirotani, Takashi Kagari, Kazuto Nishio, Kazuhiko Nakagawa
HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non-Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 28 (2) (2021)
Ryoji Kato, Koji Haratani, Hidetoshi Hayashi, Kazuko Sakai, Hitomi Sakai, Hiasto Kawakami, Kaoru Tanaka, Masayuki Takeda, Kimio Yonesaka, Kazuto Nishio, Kazuhiko Nakagawa
Nintedanib promotes antitumour immunity and shows antitumour activity in combination with PD-1 blockade in mice: potential role of cancer-associated fibroblasts. British journal of cancer 124 (5) (2020)
Satomi Watanabe, Kimio Yonesaka, Junko Tanizaki, Yoshikane Nonagase, Naoki Takegawa, Koji Haratani, Hisato Kawakami, Hidetoshi Hayashi, Masayuki Takeda, Junji Tsurutani, Kazuhiko Nakagawa
Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer. Cancer medicine 8 (3) (2019)
Kimio Yonesaka, Kaoru Tanaka, Mutsukazu Kitano, Hiasto Kawakami, Hidetoshi Hayashi, Masayuki Takeda, Kazuko Sakai, Kazuto Nishio, Katsumi Doi, Kazuhiko Nakagawa
Aberrant HER3 ligand heregulin-expressing head and neck squamous cell carcinoma is resistant to anti-EGFR antibody cetuximab, but not second-generation EGFR-TKI. Oncogenesis 8 (10) (2019)
Kimio Yonesaka, Eiji Iwama, Hidetoshi Hayashi, Shinichiro Suzuki, Ryoji Kato, Satomi Watanabe, Takayuki Takahama, Junko Tanizaki, Kaoru Tanaka, Masayuki Takeda, Kazuko Sakai, Koichi Azuma, Yasutaka Chiba, Shinji Atagi, Kazuto Nishio, Isamu Okamoto, Kazuhiko Nakagawa
Heregulin expression and its clinical implication for patients with EGFR-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors. Scientific reports 9 (1) (2019)
Kazuko Sakai, Masayuki Takeda, Shigeki Shimizu, Takayuki Takahama, Takeshi Yoshida, Satomi Watanabe, Tsutomu Iwasa, Kimio Yonesaka, Shinichiro Suzuki, Hidetoshi Hayashi, Hiasto Kawakami, Yoshikane Nonagase, Kaoru Tanaka, Junji Tsurutani, Kazumasa Saigoh, Akihiko Ito, Tetsuya Mitsudomi, Kazuhiko Nakagawa, Kazuto Nishio
A comparative study of curated contents by knowledge-based curation system in cancer clinical sequencing. Scientific reports 9 (1) (2019)
Naoki Takegawa, Yoshikane Nonagase, Kimio Yonesaka, Kazuko Sakai, Osamu Maenishi, Yusuke Ogitani, Takao Tamura, Kazuto Nishio, Kazuhiko Nakagawa, Junji Tsurutani
DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance. International journal of cancer 141 (8) (2017)